Is Pfizer a Good Stock to Buy?

When it comes to investing in pharmaceutical companies, picking the right one is crucial. These companies work on and develop drugs that could be the next cure of the century or the next flop. So the question remains, Is Pfizer a Good Stock to Buy? My answer? Yes! Let me explain why.

Financial Health: A Closer Look

Understanding the financial state of a company is like checking the oil in your car; you want to ensure everything’s running smoothly. Pfizer has shown strong revenue growth in recent years, largely due to its COVID-19 vaccine and treatments. This financial boost has increased investor interest.

Our Sponsor

Looking for another great article? Check out our friend’s article, Wealth Management: PAW vs UAW

However, keep an eye on upcoming patent expirations. When patents run out, it can mean less exclusive control over certain drugs, which may impact future revenue. So, while Pfizer’s current financials look robust, it’s essential to think long-term.

Let us take a look at their revenue over the last few years. As you can see, their revenue fluctuates a bit but overall is solid. The company is earning $50+ billion a year, this creates a solid base for the company.

• Pfizer revenue for the quarter ending March 31, 2024 was $14.879B, a 19.51% decline year-over-year.
• Pfizer revenue for the twelve months ending March 31, 2024 was $54.889B, a 41.08% decline year-over-year.
• Pfizer annual revenue for 2023 was $58.496B, a 41.7% decline from 2022.
• Pfizer annual revenue for 2022 was $100.33B, a 23.43% increase from 2021.
• Pfizer annual revenue for 2021 was $81.288B, a 95.16% increase from 2020.

If we take a look at their profit over the same period, you will see they have a large profit base. This means the company is extremely healthy and has the funds on hand to develop more drugs that can help save lives and treat existing conditions. Like their revenue, their profit fluctuates but it is healthy.

• Pfizer gross profit for the quarter ending March 31, 2024 was $11.500B, a 15.44% decline year-over-year.
• Pfizer gross profit for the twelve months ending March 31, 2024 was $31.442B, a 50.8% decline year-over-year.
• Pfizer annual gross profit for 2023 was $33.542B, a 49.17% decline from 2022.
• Pfizer annual gross profit for 2022 was $65.986B, a 30.75% increase from 2021.
• Pfizer annual gross profit for 2021 was $50.467B, a 52.16% increase from 2020.

Market Position: Standing Tall

Pfizer’s position in the market is like a giant oak tree in a forest of shrubs. With a strong brand reputation and extensive distribution network, Pfizer is well-respected among healthcare providers. This solid standing helps the company maintain a competitive edge.

Moreover, the global healthcare market is expected to expand, and Pfizer can benefit from this growth. Think of it like being in the right place at the right time; the potential for profit is there if Pfizer continues to innovate and meet market demands.

When you think of drug companies, the Pfizer brands stands out. If you know it, trust it and expect it to do what you want it too. Its position and brand recognition makes this a power house of a company.

Is Pfizer a Good Stock to Buy? My answer?

 Yes, I do. I currently own this stock and plan to hold it long-term. My goal with this company is for it to remain a forever buy. If you are looking to get into this sector, I suggest adding Pfizer to your portfolio. They currently have a dividend yield of 5.69% and an annual payout of $1.68. What is there not to love about that?

Disclaimer

I am not a financial advisor or licensed stock broker. This is my opinion. It’s essential to consider that no investment is without risks. As with any investment decision, thorough research and consideration of your financial goals and risk tolerance are crucial.